- Home
- DMAC vs VTYX Comparison
DMAC vs VTYX Comparison
Compare DMAC & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- VTYX
- Stock Information
- Founded
- DMAC 2000
- VTYX 2018
- Country
- DMAC United States
- VTYX United States
- Employees
- DMAC N/A
- VTYX N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- DMAC Health Care
- VTYX Health Care
- Exchange
- DMAC Nasdaq
- VTYX Nasdaq
- Market Cap
- DMAC 185.1M
- VTYX 148.4M
- IPO Year
- DMAC N/A
- VTYX 2021
- Fundamental
- Price
- DMAC $4.23
- VTYX $2.17
- Analyst Decision
- DMAC Strong Buy
- VTYX Buy
- Analyst Count
- DMAC 3
- VTYX 7
- Target Price
- DMAC $7.00
- VTYX $7.71
- AVG Volume (30 Days)
- DMAC 34.2K
- VTYX 818.1K
- Earning Date
- DMAC 11-13-2024
- VTYX 11-15-2024
- Dividend Yield
- DMAC N/A
- VTYX N/A
- EPS Growth
- DMAC N/A
- VTYX N/A
- EPS
- DMAC N/A
- VTYX N/A
- Revenue
- DMAC N/A
- VTYX N/A
- Revenue This Year
- DMAC N/A
- VTYX N/A
- Revenue Next Year
- DMAC N/A
- VTYX N/A
- P/E Ratio
- DMAC N/A
- VTYX N/A
- Revenue Growth
- DMAC N/A
- VTYX N/A
- 52 Week Low
- DMAC $2.12
- VTYX $1.79
- 52 Week High
- DMAC $4.95
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- DMAC 45.24
- VTYX 49.39
- Support Level
- DMAC $4.14
- VTYX $2.10
- Resistance Level
- DMAC $4.48
- VTYX $2.36
- Average True Range (ATR)
- DMAC 0.18
- VTYX 0.12
- MACD
- DMAC -0.03
- VTYX -0.00
- Stochastic Oscillator
- DMAC 34.88
- VTYX 34.01
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.